Second quarter company results show wide variations.

Affymetrix recorded second quarter 2002 revenues of $70.7 million, a 42.6% increase from the second quarter of 2001. Excluding $5.6 million in sales to Perlegen Sciences, revenues increased 40.0% to $58.6 million. Product revenues were driven by the shipment of 97,000 arrays during the quarter.

Revenue from licensing fees, royalties and research totaled $6.4 million for quarter, up 36.1% from a year ago. Operating income was $1.5 million for the second quarter, compared to an operating loss of $12.3 million in the same period of 2001. Revenues of $60-$62 million are forecasted for the third quarter of 2002, while sales of $248 million are expected for the year.

Beckman Coulter's second quarter 2002 sales for Life Science Research grew 0.1% to $112.1 million. Within the segment, Robotic Automation and Genetic Analysis sales increased 15% to $43.7 million. Centrifuge and Analytical System sales declined 7.6% to $68.4 million. Operating income increased 5.3% to $67.8 million. For the third quarter, Beckman Coulter expects total company revenue to increase 10%.

Biacore sales for the second quarter of 2002 rose 26.3% to SEK 154.6 million ($15.4 million = SEK 10.02 = $1) from SEK 122.4 million ($11.7 million = SEK 10.45 = $1) in the same quarter of 2001. Operating profits reached SEK 32.2 million ($3.2 million = SEK 10.02 = $1), a 847.1% increase from a year ago. Sales to Europe declined 8.3%, while sales to Asia-Pacific and the Americas increased 33.7% and 48.0%, respectively.

Bio-Rad Laboratories achieved sales of $215.0 million for the second quarter of 2002, up 9.9% year over year. Life Science sales rose 14.8%, and Clinical Diagnostic sales rose 9%.

Bruker AXS posted second quarter 2002 revenues of $24.0 million, up 19.0% year over year. Operating profits dropped 84.8% to $498.6 million. R&D increased 46.4% to $2.8 million. Bruker AXS forecasts 2002 sales growth of over 20% to $99-$101 million.

For the first half of 2002, Genetix, reported a decline in revenues of 13.2% to 6.3 million [pounds sterling] ($9.1 million = 0.69 [pounds sterling] = $1) from 7.3 million [pounds sterling] ($10.4 = 0.70 [pounds sterling] = $1) a year ago. Operating profits fell 64.7% to 0.6 million [pounds sterling] ($0.9 million = 0.69 [pounds sterling] = $1). Instrumentation sales were down 22.7% to 4.5 million [pounds sterling] ($6.5 million = 0.69 [pounds sterling] = $1), while consumables and services sales were up 23.0% to 1.9 million [pounds sterling] ($2.8 million = 0.69 [pounds sterling] = $1).

Harvard Bioscience reported second quarter 2002 revenues of $13.7 million, up 38.0% from the same quarter of 2001. Operating profits increased 76.1% to $2.1 million.

Mettler-Toledo's second quarter 2002 sales reached $296.5 million, 6.2% higher than second quarter 2001 sales. Profits from operations increased 1.5% to $41.0 million. In the second quarter, the company took a pre-tax restructuring charge of $28.7 million.

Molecular Devices ended the second quarter of 2002 with revenues of $25.4 million, 6.1% more than the $24.0 million reported for the same quarter of 2001. Operating profits declined 18.6% to $2.2 million. Third quarter 2002 revenues are expected to range from $26-$28 million, with 2002 revenues are forecasted at $104-$108 million. Fiscal 2003 revenues are forecasted at $120-$130 million.

Qiagen posted a 10.1% increase in sales to $72.7 million in the second quarter of 2002, from $66.0 million a year ago. Operating income dropped 37.0% to $9.4 million. Sales of separation, purification and handling consumables increased 20%.

Veeco Instruments posted a 31.0% decline in revenues for the second quarter of 2002 .to $77.3 million Operating profits were $2.1 million for the second quarter, down 87.1%.